DRIADA SHIPS ONLY TO GERMANY, UK, FRANCE, ITALY, SPAIN, POLAND, ROMANIA, NETHERLANDS, BELGUIM, CZECH REPUBLIC, GREECE, PORTUGAL, HUNGARY, BULGARIA, SLOVAKIA, CROTIA, SOLVENIA, LUXEMBOURG, ANDORRA, MONACO and SAN MARINO.
DO NOT SHIP TO ISLAND AREAS OF EUROPE THAT ARE PART OF THE EU SUCH AS CANARY ISLANDS, SWITZERLAND, AUSTRIA, ESTONIA, LATVIA , LITHUANIA , ICELAND SWEDEN, NORWAY, DENMARK, FINLAND, GIBRALTAR, SOUTH KOREA, ISRAEL, AUSTRALIA, USA and CANADA!!!
We newly started our product review feature.
Be the first to comment on this product.
Please login to comment on this product.
Tirzepatide is an innovative pharmacological agent that represents a significant advancement in the treatment of type 2 diabetes mellitus (T2DM) and obesit. This drug is a dual agonist that targets both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. These incretin hormones are naturally occurring peptides involved in the regulation of glucose homeostasis and energy balance. By simultaneously targeting these pathways, tirzepatide exerts a synergistic effect that enhances its efficacy in managing hyperglycemia and promoting weight loss, distinguishing it from existing therapies that typically target only the GLP-1 receptor.